Atlas Trials

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Clinical trial NCT03121586 · TERMINATED

Trial details

NCT number
NCT03121586
Sponsor
ACADIA Pharmaceuticals Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2017-01-01
Primary completion
2024-04-30
Enrollment
995

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.